Latest News
Genentech Issues Community Letter Regarding Emugrobart
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The decision to stop clinical development […]
Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh in Scotland
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Evrysdi Risdiplam Tablet Is Now Approved For Broader Use In SMA
We’re excited to share an important update for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved a label expansion for Evrysdi® (risdiplam) tablets, […]
Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Novartis Releases Winter SMA Community Update Letter
Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with SMA, offering a one-time gene […]
Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]